Header Logo

Katherine Griem

Concepts (159)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
19
2017
411
2.120
Why?
Brachytherapy
10
2017
46
1.460
Why?
Radiation Injuries
3
2012
29
1.070
Why?
Radiotherapy Planning, Computer-Assisted
5
2017
52
0.930
Why?
Radiotherapy, Conformal
5
2011
20
0.910
Why?
Skin
2
2012
123
0.740
Why?
Mastectomy, Segmental
8
2009
29
0.660
Why?
Radiotherapy Dosage
14
2017
101
0.520
Why?
Radiotherapy, Adjuvant
5
2017
53
0.460
Why?
Radiometry
4
2017
25
0.450
Why?
Carcinoma, Ductal, Breast
4
2008
33
0.420
Why?
Prone Position
2
2011
32
0.410
Why?
Thermal Conductivity
1
2012
2
0.400
Why?
Thermography
1
2012
13
0.400
Why?
Radiotherapy, Intensity-Modulated
2
2009
36
0.390
Why?
Lymph Nodes
2
2011
72
0.380
Why?
Breast
3
2010
25
0.360
Why?
Combined Modality Therapy
12
2010
305
0.340
Why?
Genital Neoplasms, Female
1
2010
15
0.340
Why?
Heart
2
2009
62
0.340
Why?
Axilla
2
2008
14
0.330
Why?
Female
26
2012
15271
0.320
Why?
Taxoids
1
2009
11
0.320
Why?
Radiodermatitis
1
2009
4
0.320
Why?
Antineoplastic Agents
2
2009
202
0.300
Why?
Middle Aged
18
2011
9011
0.240
Why?
Humans
32
2017
27185
0.240
Why?
Posture
1
2003
63
0.210
Why?
Adult
17
2011
7886
0.190
Why?
Head and Neck Neoplasms
4
1997
147
0.190
Why?
Carcinoma, Squamous Cell
4
1997
171
0.190
Why?
Aged
15
2011
9053
0.180
Why?
Feasibility Studies
3
2011
220
0.180
Why?
Intraoperative Care
2
2017
42
0.160
Why?
Lymph Node Excision
2
1996
27
0.160
Why?
Radiography
4
2009
622
0.150
Why?
Supine Position
2
2011
21
0.150
Why?
Mice
2
2012
1408
0.140
Why?
Treatment Failure
2
2008
160
0.140
Why?
Retrospective Studies
7
2013
3561
0.130
Why?
Lung
3
2011
169
0.130
Why?
Neoplasm Staging
4
2010
367
0.130
Why?
Animals
2
2012
3642
0.110
Why?
Imaging, Three-Dimensional
2
2006
195
0.110
Why?
Radiation Oncology
1
2013
14
0.110
Why?
Accreditation
1
2013
15
0.110
Why?
Pilot Projects
3
2012
417
0.100
Why?
Body Water
1
2012
2
0.100
Why?
Mice, Hairless
1
2012
2
0.100
Why?
Tomography
1
2012
13
0.100
Why?
Education, Medical, Graduate
1
2013
79
0.100
Why?
Fluorouracil
5
1999
46
0.100
Why?
Physicians
1
2013
124
0.090
Why?
Iridium Radioisotopes
2
2008
3
0.090
Why?
Logistic Models
1
2012
398
0.090
Why?
Monte Carlo Method
2
2017
50
0.090
Why?
Electronics
2
2010
9
0.090
Why?
Clinical Competence
1
2013
210
0.090
Why?
Antineoplastic Combined Chemotherapy Protocols
6
1997
246
0.080
Why?
Disease-Free Survival
3
2007
180
0.080
Why?
Internship and Residency
1
2013
216
0.080
Why?
Treatment Outcome
6
2010
3536
0.080
Why?
Radioisotope Teletherapy
1
1989
1
0.080
Why?
Neoplasm Recurrence, Local
6
1996
219
0.080
Why?
Contracture
1
2009
12
0.080
Why?
Neoplasms, Radiation-Induced
1
1989
12
0.080
Why?
Organ Size
1
2009
94
0.080
Why?
Cisplatin
4
1997
61
0.080
Why?
Biomarkers
1
2012
558
0.080
Why?
Liposarcoma
1
1989
17
0.080
Why?
Lymphatic Metastasis
2
2008
92
0.080
Why?
Thyroid Neoplasms
1
1989
44
0.080
Why?
Heart Ventricles
1
2009
92
0.080
Why?
Rectal Neoplasms
1
1989
15
0.080
Why?
Carcinoma, Lobular
2
2007
23
0.080
Why?
Follow-Up Studies
7
2010
1801
0.080
Why?
Models, Biological
2
2004
321
0.070
Why?
Carcinoma in Situ
1
2007
10
0.070
Why?
Mastectomy
1
1987
36
0.070
Why?
Aged, 80 and over
5
2009
4817
0.070
Why?
Tomography, X-Ray Computed
3
2007
692
0.070
Why?
Cell Division
2
1996
83
0.060
Why?
Electrons
1
2004
17
0.060
Why?
Theophylline
1
1983
2
0.050
Why?
1-Methyl-3-isobutylxanthine
1
1983
6
0.050
Why?
Radiation-Protective Agents
1
1983
4
0.050
Why?
Cyclic AMP
1
1983
32
0.050
Why?
Reference Values
1
2003
186
0.050
Why?
Chemotherapy, Adjuvant
3
1996
84
0.050
Why?
Time Factors
4
1996
1442
0.040
Why?
S Phase
2
1996
11
0.040
Why?
Antimetabolites, Antineoplastic
1
1999
18
0.040
Why?
Tongue Neoplasms
1
1999
19
0.040
Why?
Ventricular Dysfunction, Left
1
1999
35
0.040
Why?
Carcinoma
1
1999
67
0.040
Why?
Antineoplastic Agents, Hormonal
2
1996
19
0.040
Why?
Tamoxifen
2
1996
30
0.040
Why?
Biopsy
2
1996
200
0.040
Why?
Neoplasm Invasiveness
2
1995
94
0.040
Why?
Water
1
2017
30
0.040
Why?
Dose-Response Relationship, Radiation
2
2007
9
0.030
Why?
Mouth Mucosa
1
1996
13
0.030
Why?
Paclitaxel
1
1996
51
0.030
Why?
Cell Count
1
1996
81
0.030
Why?
Cellulitis
1
1996
10
0.030
Why?
Esophageal Neoplasms
1
1997
50
0.030
Why?
Adenocarcinoma
1
1997
140
0.030
Why?
Immunohistochemistry
1
1996
374
0.030
Why?
Apoptosis
1
1996
214
0.030
Why?
Cell Cycle
1
1995
34
0.030
Why?
Male
7
1999
14834
0.030
Why?
Survival Rate
1
1995
344
0.030
Why?
Neoplasms, Second Primary
1
1994
38
0.030
Why?
Postoperative Care
2
1996
135
0.030
Why?
Age Factors
1
1995
774
0.030
Why?
Hodgkin Disease
1
1993
19
0.030
Why?
Safety
1
2010
37
0.020
Why?
Cobalt Radioisotopes
1
1989
3
0.020
Why?
Nasopharyngeal Neoplasms
1
1989
3
0.020
Why?
Anal Canal
1
1989
3
0.020
Why?
Child
2
1993
1298
0.020
Why?
Preoperative Care
1
1989
119
0.020
Why?
Statistics as Topic
1
1987
103
0.020
Why?
Random Allocation
1
1987
123
0.020
Why?
Hemibody Irradiation
1
2007
2
0.020
Why?
United States
1
2013
2056
0.020
Why?
Tumor Burden
1
2007
28
0.020
Why?
Clinical Trials as Topic
1
1987
216
0.020
Why?
Survival Analysis
2
1997
260
0.020
Why?
Equipment Design
1
2006
139
0.020
Why?
Relative Biological Effectiveness
1
2004
5
0.010
Why?
Particle Accelerators
1
2004
5
0.010
Why?
Body Burden
1
2004
7
0.010
Why?
Scattering, Radiation
1
2004
33
0.010
Why?
Models, Statistical
1
2004
127
0.010
Why?
Cell Survival
1
1983
119
0.010
Why?
Actuarial Analysis
2
1995
8
0.010
Why?
Cell Line
1
1983
272
0.010
Why?
Computer Simulation
1
2004
196
0.010
Why?
Risk Factors
1
1989
2324
0.010
Why?
Heart Diseases
1
1999
62
0.010
Why?
Infusions, Intravenous
1
1997
52
0.010
Why?
Esophagectomy
1
1997
23
0.010
Why?
Carcinoma, Intraductal, Noninfiltrating
1
1996
12
0.010
Why?
Anti-Inflammatory Agents
1
1996
77
0.010
Why?
Idoxuridine
1
1995
2
0.010
Why?
Mitotic Index
1
1995
6
0.010
Why?
G2 Phase
1
1995
5
0.010
Why?
Bromodeoxyuridine
1
1995
10
0.010
Why?
DNA, Neoplasm
1
1995
24
0.010
Why?
Recurrence
1
1996
313
0.010
Why?
Lymphoma
1
1995
36
0.010
Why?
Regression Analysis
1
1995
260
0.010
Why?
Kinetics
1
1995
181
0.010
Why?
Proportional Hazards Models
1
1995
348
0.010
Why?
Contraindications
1
1994
31
0.010
Why?
Anti-Bacterial Agents
1
1996
368
0.010
Why?
Postoperative Complications
1
1996
927
0.010
Why?
Adolescent
1
1993
2194
0.000
Why?
Griem's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (159)
Explore
_
Co-Authors (11)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_